276 related articles for article (PubMed ID: 18805967)
1. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Johnson DC; Corthals S; Ramos C; Hoering A; Cocks K; Dickens NJ; Haessler J; Goldschmidt H; Child JA; Bell SE; Jackson G; Baris D; Rajkumar SV; Davies FE; Durie BG; Crowley J; Sonneveld P; Van Ness B; Morgan GJ
Blood; 2008 Dec; 112(13):4924-34. PubMed ID: 18805967
[TBL] [Abstract][Full Text] [Related]
2. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Johnson DC; Corthals SL; Walker BA; Ross FM; Gregory WM; Dickens NJ; Lokhorst HM; Goldschmidt H; Davies FE; Durie BG; Van Ness B; Child JA; Sonneveld P; Morgan GJ
J Clin Oncol; 2011 Mar; 29(7):797-804. PubMed ID: 21245421
[TBL] [Abstract][Full Text] [Related]
3. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.
Almasi M; Sevcikova S; Slaby O; Kaisarova P; Maisnar V; Penka M; Pika T; Pour L; Radocha J; Scudla V; Svachova H; Hajek R
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):414-20. PubMed ID: 21859556
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
Bagratuni T; Kastritis E; Politou M; Roussou M; Kostouros E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanelias N; Terpos E; Dimopoulos MA
Am J Hematol; 2013 Sep; 88(9):765-70. PubMed ID: 23757261
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide.
Tewari P; Kenny E; Staines A; Chanock S; Browne P; Lawler M
Blood; 2009 May; 113(22):5691-2. PubMed ID: 19478055
[No Abstract] [Full Text] [Related]
6. Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
Alkindi S; Dennison D; Pathare A
Arch Med Res; 2008 Feb; 39(2):257-8. PubMed ID: 18164975
[No Abstract] [Full Text] [Related]
7. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.
Kato A; Takano H; Ichikawa A; Koshino M; Igarashi A; Hattori K; Nagata K
Thromb Res; 2013 Feb; 131(2):140-4. PubMed ID: 23232090
[TBL] [Abstract][Full Text] [Related]
8. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis.
Rus C; Bazzan M; Palumbo A; Bringhen S; Boccadoro M
J Thromb Haemost; 2004 Nov; 2(11):2063-5. PubMed ID: 15550053
[No Abstract] [Full Text] [Related]
10. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
Baz R; Li L; Kottke-Marchant K; Srkalovic G; McGowan B; Yiannaki E; Karam MA; Faiman B; Jawde RA; Andresen S; Zeldis J; Hussein MA
Mayo Clin Proc; 2005 Dec; 80(12):1568-74. PubMed ID: 16342649
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Anaissie EJ; Coleman EA; Goodwin JA; Kennedy RL; Lockhart KD; Stewart CB; Coon SK; Bailey C; Barlogie B
Cancer; 2012 Jan; 118(2):549-57. PubMed ID: 21720994
[TBL] [Abstract][Full Text] [Related]
12. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
13. Genetic variations in multiple myeloma II: association with effect of treatment.
Vangsted A; Klausen TW; Vogel U
Eur J Haematol; 2012 Feb; 88(2):93-117. PubMed ID: 21883476
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and thrombosis. A meta-analysis.
El Accaoui RN; Shamseddeen WA; Taher AT
Thromb Haemost; 2007 Jun; 97(6):1031-6. PubMed ID: 17549307
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Hussein MA
Thromb Haemost; 2006 Jun; 95(6):924-30. PubMed ID: 16732369
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
[TBL] [Abstract][Full Text] [Related]
18. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.
Ipek Y; Fehmi H; Sevgi BK; Deniz S
J Thromb Thrombolysis; 2012 Feb; 33(2):197-201. PubMed ID: 21904842
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
Uaprasert N; Voorhees PM; Mackman N; Key NS
Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
